Analyst Research

Report Title Price
Provider : ValuEngine, Inc.
Provider : Stock Traders Daily
Provider : Pechala's Reports
Provider : Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Health Canada approves Celgene Corp's POMALYST patients with progressive multiple myeloma

Tuesday, 11 Feb 2014 06:30am EST 

Celgene Corp:Says Health Canada has approved POMALYST oral therapy in combination with dexamethasone, for patients with multiple myeloma for whom both lenalidomide and bortezomib have failed, who have received at least two prior treatment regimens and have demonstrated disease progression on their last regimen.POMALYST received priority review status by Health Canada due to the high unmet medical need that exists and the clinical value that the treatment brings to patients and physicians.The Health Canada approval of POMALYST was based on the MM-003 pivotal study, which was published in The Lancet Oncology in Oct 2013.POMALYST is expected to be commercially available in Mar.POMALYST is a trademark of the company. 

Company Quote

0.34 +0.30%
27 Nov 2015